Ceesay Abraham sold $374K of RAPP
Ceesay Abraham (Chief Executive Officer) sold 8,210 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $45.61 ($45.56–$46.01, $0.37M total) across 2 trades on 2026-09-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may trigger short‑term selling pressure but likely limited given the insider's remaining stake.
Market read
A modest insider sale that could slightly affect RAPP's stock price.
What to watch
CEO retains a sizable stake (458,977 shares) indicating continued confidence.
Background
Form 4 filing discloses insider transactions required by the SEC.
Ticker impact
CEO Ceesay Abraham sold 8,210 shares for $374,498 via a 10b5‑1 plan on 2026‑09‑08.
Potential modest downside of 1‑2% over the next few days.
The sale amount is modest relative to holdings but is a direct insider disposition, often viewed negatively by traders.
Market effects
Limited; only affects biotech sector sentiment marginally.
None; impact confined to US biotech investors.
Low; no broader market effect.
Counterpoint
The sale could be routine under a pre‑arranged plan, not indicative of fundamentals.
Key entities
- CompanyRapport Therapeutics, Inc.
Biotech firm listed on NASDAQ under ticker RAPP.
- ExecutiveCeesay Abraham
Chief Executive Officer of Rapport Therapeutics.